Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

In Vivo Assessment of Silver Biomaterial Nano-Toxicity

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
mark munger, University of Utah
ClinicalTrials.gov Identifier:
NCT01243320
First received: November 16, 2010
Last updated: July 12, 2013
Last verified: July 2011
  Purpose

Hypothesis: Various time-length exposures of the American Biotech Laboratory 10 ppm silver solution will not evidence in clinically significant toxicity in healthy human volunteers.

Aim 1: Quantify Comprehensive Metabolic Panel, Urinalysis, and CBC with Platelet Count Changes from exposure to 10 ppm Silver Solution.

Routine standardized blood and urine analyses will be collected at baseline and compared to end of each time-length exposure.

Aim 2: Quantify Silver in Whole Blood and Urine by Measurement of Silver Metallic Ions (Ag0).

The daily amount of Ag0 ingested will be calculated (Intake) and compared to the collection of Ag0 serum and urine concentrations from baseline to the start of next dosing interval (Output) on the final day of each time-length exposure.

Aim 3: Quantify granulocyte and agranulocyte counts, measuring presence of reactive oxygen species (ROS), and determining presence of pro-inflammatory genetic markers from induced sputum.

Induced sputum will be collected and analyzed for white blood cell counts presence of reactive oxygen species after the last dose on the final day of time-length exposure.

Aim 4: Qualify Silver Nanoparticle Retention in Human Organ Systems On the last day of each phase of the study, all eligible subjects without will undergo a cardiac and abdominal MRI to identify retention Ag0 nanoparticles.


Condition Intervention Phase
Healthy Volunteers
Drug: ASAP Solution 10 ppm
Drug: ASAP Solution 10 ppm Diluent
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Official Title: In Vivo Assessment of Silver Biomaterial Nano-Toxicity

Further study details as provided by University of Utah:

Primary Outcome Measures:
  • Quantify Comprehensive Metabolic Panel, Urinalysis, and CBC with Platelet Count Changes from exposure to 10 ppm Silver Solution. [ Time Frame: 3, 7, 14 days ] [ Designated as safety issue: Yes ]
    Routine standardized blood and urine analyses will be collected at baseline and compared to end of each time-length exposure.


Secondary Outcome Measures:
  • Quantify Silver in Whole Blood and Urine by Measurement of Silver Metallic Ions (Ag0). [ Time Frame: 3, 7, 14 days ] [ Designated as safety issue: Yes ]
    The daily amount of Ag0 ingested will be calculated (Intake) and compared to the collection of Ag0 serum and urine concentrations from baseline to the start of next dosing interval (Output) on the final day of each time-length exposure.

  • Quantify granulocyte and agranulocyte counts, measuring presence of reactive oxygen species (ROS), and determining presence of pro-inflammatory genetic markers from induced sputum. [ Time Frame: 3, 7, 14 days ] [ Designated as safety issue: Yes ]
    Induced sputum will be collected and analyzed for white blood cell counts presence of reactive oxygen species after the last dose on the final day of time-length exposure.

  • Qualify Silver Nanoparticle Retention in Human Organ Systems [ Time Frame: 3, 7, 14 days ] [ Designated as safety issue: Yes ]
    On the last day of each phase of the study, all eligible subjects without will undergo a cardiac and abdominal MRI to identify retention Ag0 nanoparticles.


Enrollment: 37
Study Start Date: December 2010
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: ASAP Solution 10 ppm, Silver Biotics 10ppm
Silver Nanoparticles 10 ppm Chemistry, Urinalysis, Hematology, and Whole Silver Concentration. Lung tissue via sputum analysis. Cardiac and Abdominal MRI.
Drug: ASAP Solution 10 ppm
Silver nanoparticles at 10ppm
Other Name: Silver Biotics 10 ppm
Placebo Comparator: Silver Biotics 10 ppm Diluent
Silver Nanoparticles 10 ppm Diluent Chemistry, Urinalysis, Hematology, and Whole Silver Concentration. Lung tissue via sputum analysis. Cardiac and Abdominal MRI.
Drug: ASAP Solution 10 ppm Diluent
Diluent without active ingredient

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects must be > 18-80 years old will be included.

Exclusion Criteria:

  • Females of child-bearing potential, defined as women physically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means will be excluded unless they are using 2 barrier birth control methods (i.e., diaphragm, condom, intrauterine device, sponge or spermicide) or hormonal contraceptive method.
  • Any female subject who is nursing will be excluded. Subject with has a history of heavy metal allergy (including silver) or a history of asthma or COPD or renal impairment defined by a creatinine clearance below 30 ml/min.
  • Subjects with symptoms of an active upper respiratory infection at time of consent will also be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01243320

Locations
United States, Utah
University of Utah Hospital and Clinics
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
University of Utah
Investigators
Principal Investigator: Mark A Munger, Pharm.D> University of Utah
  More Information

No publications provided by University of Utah

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: mark munger, Professor, University of Utah
ClinicalTrials.gov Identifier: NCT01243320     History of Changes
Other Study ID Numbers: 40281
Study First Received: November 16, 2010
Last Updated: July 12, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Pharmaceutical Solutions
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014